Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07218380 · ClinicalTrials.gov registry record · Phase 3
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
A Phase 3 study of Neoplasm Metastasis and Urinary Bladder Neoplasms, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
- 20
- Study locations
NCT07218380 is a Phase 3 study of Neoplasm Metastasis and Urinary Bladder Neoplasms that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 450 participants, above the 405-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (11% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT07218380, a Phase 3 study of Neoplasm Metastasis and Urinary Bladder Neoplasms, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Study participation could last up to approximately 6 years.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- OTHER Placebo
- DRUG EV
- DRUG Vepugratinib
Study Locations (20)
California
- Chao Family Comprehensive Cancer Center and Ambulatory Care (CIACC) - Irvine - Irvine
- TRIO-US (Translational Research in Oncology-US) - Los Angeles
- UCLA Hematology/Oncology - Santa Monica - Los Angeles
- University of California, Irvine (UCI) Health - UC Irvine Medical Center - Orange
- University of California Davis (UC Davis) Comprehensive Cancer Center - Sacramento
- UCSF Medical Center at Mission Bay - San Francisco
- Hunt Cancer Institute, an Affiliate of Cedars-Sinai Cancer (TMPN) - Torrance
Indiana
- Parkview Research Center at Parkview Regional Medical Center - Fort Wayne
- Indiana University Melvin and Bren Simon Cancer Center - Indianapolis
- Franciscan Health - Indianapolis
Colorado
- AdventHealth Medical Group - Porter - Denver
- Colorado West Healthcare System - Grand Valley Oncology - Grand Junction
Illinois
- University of Illinois at Chicago - Chicago
- University of Chicago Medical Center - Chicago
Alabama
- Clearview Cancer Institute - Huntsville
Arizona
- The University of Arizona Cancer Center - North Campus - Tucson
Florida
- AdventHealth Orlando - Orlando
Idaho
- St. Luke's Cancer Institute: Boise - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2025-12-12 |
| Est. Completion | 2033-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07218380
The ClinicalTrials.gov registry entry for NCT07218380 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 405-participant average among 41 other Neoplasm Metastasis trials with a reported enrollment target (11% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Neoplasm Metastasis appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT07218380 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Indiana, Colorado.
Frequently Asked Questions
What is clinical trial NCT07218380 about?
NCT07218380 is a clinical study titled "A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract". The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Study...
What is the current status of trial NCT07218380?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2025-12-12. Estimated completion is 2033-05.
What conditions does trial NCT07218380 study?
This clinical trial studies the following conditions: Neoplasm Metastasis, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell.
What interventions are being tested in trial NCT07218380?
The interventions under investigation include: Pembrolizumab (DRUG), Placebo (OTHER), EV (DRUG), Vepugratinib (DRUG).
Who is sponsoring clinical trial NCT07218380?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07218380 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasm Metastasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RECRUITING · Phase 3
-
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
RECRUITING · Phase 3
-
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RECRUITING · Phase 3
-
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.